Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | PTPRO | Q16827 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5045150 | 0.92 | FFAR1 (0.47) | PTPN11PTPROFFAR1PTGESFFAR4 | |
| SCHEMBL5045341 | 0.88 | PPARA (0.44) | — | |
| SCHEMBL4672605 | 0.87 | FFAR1 (0.56) | PTPN11PTPROFFAR1PTGESFFAR4 | |
| SCHEMBL4965330 | 0.85 | PTGES (0.47) | PTPN11PTPROFFAR1PTGESALDH1A1 | |
| SCHEMBL1853423 | 0.84 | KCNH2 (0.44) | PTPN11PTPROALDH1A1PLK1FAAH | |
| SCHEMBL1858934 | 0.84 | KCNH2 (0.44) | PTPN11PTPROALDH1A1PLK1FAAH | |
| SCHEMBL4314702 | 0.84 | PTPN11 (0.48) | PTPN11PTPROFFAR1PTGESALDH1A1 | |
| SCHEMBL4672519 | 0.84 | PTPN11 (0.48) | PTPN11PTPROFFAR1PTGESALDH1A1 | |
| Acetic Acid SCHEMBL27717389 | 0.84 | PTPN11 (0.48) | PTPN11PTPROFFAR1PTGESALDH1A1 | |
| SCHEMBL1733849 | 0.84 | PTPN11 (0.48) | PTPN11PTPROFFAR1PTGESALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | LABORATORIES SERONO SA (CH) | 2008-08-28 | — | — | US | claimed |
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | LABORATORIES SERONO SA (CH) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | PPP1R1B, PPP5C, PPP3CA | PTPN11 458/4885PTPRO 86/4885FFAR1 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.